Study demonstrates cells can acquire new functions through transcriptional regulatory network

Mar 14, 2012

Researchers at the RIKEN Omics Science Center (OSC) have successfully developed and demonstrated a new experimental technique for producing cells with specific functions through the artificial reconstruction of transcriptional regulatory networks. As an alternative to induced pluripotent stem cells, the technique promises to enable faster and more efficient production of functional cells for use in cancer therapy and a variety of other areas.

Starting with the first-ever production of induced (iPS cells) in 2006, cell reprogramming - the genetic conversion of cells from one type to another - has revolutionized stem cell research and opened the door to countless new medical applications. Inducing such reprogramming, however, is difficult, inefficient and time-consuming, involving a largely hit-or-miss process of selecting candidate genes.

In the current study, the OSC research team explored an alternative to iPS cells based on the use of transcriptional regulatory networks (TRNs), networks of transcription factors and the genes they regulate. Previous research by the team characterized the dynamic regulatory activities of such transcription factors during from immature cell (monoblast) to developed (monocyte-like) cell using human acute monocytic lines (THP-1). Their findings led them to hypothesize that functional characteristics of the cell-type are maintained by its specific TRN.

Their new paper builds on this hypothesis, establishing a series of new methods for identifying transcription factors (TFs) for the monocyte network, which play a key role in inducing cell-specific functions. Four core TF genes of the monocyte TRN, identified using this approach, were introduced into human , expression of which activated monocytic functions including phagocytosis, inflammatory response and chemotaxis. Genome-wide of this reprogrammed cell showed monocyte-like , demonstrating that reconstruction of a functional TRN can be achieved by introducing core TRN elements into unrelated cell types.

Published in the journal PLoS ONE, the newly-developed methods open the door to a new form of direct cell reprogramming for clinical use which avoids the pitfalls of embryonic stem (ES) and induced pluripotent stem (iPS) cells, charting a course toward novel applications in regenerative medicine and drug discovery.

Explore further: YEATS protein potential therapeutic target for cancer

add to favorites email to friend print save as pdf

Related Stories

Stem cells reverse disease in a model of Parkinson's disease

May 16, 2011

In a new study to be published in the Journal of Clinical Investigation, researchers compared the ability of cells derived from different types of human stem cell to reverse disease in a rat model of Parkinson disease and id ...

Key protein reveals secret of stem cell pluripotency

Sep 06, 2011

A protein that helps maintain mouse stem cell pluripotency has been identified by researchers at the RIKEN Omics Science Center. The finding, published in the August issue of Stem Cells (first published online ...

Recommended for you

YEATS protein potential therapeutic target for cancer

15 hours ago

Federal Express and UPS are no match for the human body when it comes to distribution. There exists in cancer biology an impressive packaging and delivery system that influences whether your body will develop cancer or not.

Precise and programmable biological circuits

17 hours ago

A team led by ETH professor Yaakov Benenson has developed several new components for biological circuits. These components are key building blocks for constructing precisely functioning and programmable bio-computers.

User comments : 0